[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Democritus University of Thrace\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":136},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,77,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100639027","evaluation-of-the-effectiveness-of-three-tear-substitute-formulations-in-postoperative-discomfort-after-cataract-surgery-100639027",false,"NCT07581548","Evaluation of the Effectiveness of Three Tear Substitute Formulations in Postoperative Discomfort After Cataract Surgery","Evaluation of the Effectiveness of Three Tear Substitute Formulations in Postoperative Discomfort After Cataract Surgery: A Non- Interventional, Observational Study","DRY-CAT","Inclusion Criteria:\n\nDiagnosis of senile cataract with stage 2 or 3 nuclear opalescence according to the - Lens Opacities Classification System III (LOCS-3) grading scale\n\nExclusion Criteria:\n\n1. Former incisional surgery\n2. Former diagnosis of corneal disease\n3. Autoimmune diseases\n4. Mental diseases","ALL","45 Years","85 Years",{"count":21,"type":22},300,"ESTIMATED","OBSERVATIONAL","The primary objective of this study is the assessment of three tear substitute formulations in terms of postoperative discomfort following cataract extraction surgery by means of phacoemulsification and intraocular lens implantation.",[26,27],"Cataract","Dry Eye",[29,30,31,32],"dry eye","cataract surgery","sodium hyaluronate","artificial tears","NOT_YET_RECRUITING","2026-05-06",{"date":36,"type":37},"2026-05-12","ACTUAL",{"date":39,"type":22},"2026-05-01",{"date":41,"type":22},"2027-05-01",{"name":43,"class":44},"Democritus University of Thrace","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":58,"studyType":23,"phases":4,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":45},"100598936","luminous-efficiency-function-v-of-patients-that-underwent-pseudophakic-presbyopic-corrections-with-edof-iols-100598936","NCT07077967","Luminous Efficiency Function V(λ)' of Patients That Underwent Pseudophakic Presbyopic Corrections With EDOF IOLs","Impact of Artificial Lighting on Visual Acuity After Presbyopia Correction With an Extended Depth of Focus Intraocular Lens: Introduction of a Modified Luminous Efficiency Function V(λ)'","V(λ)'_EDOF","Inclusion Criteria:\n\n* age between 45 to 75 years\n\nExclusion Criteria:\n\n* astigmatism \\>1.00 diopters\n* glaucoma\n* former incisional eye surgery\n* corneal or fundus disease\n* diabetes mellitus\n* autoimmune diseases\n* neurological or psychiatric diseases\n* posterior capsule rupture or lens misalignment\n* postoperative uncorrected distance visual acuity \\\u003C 8\u002F10.",true,"75 Years",{"count":57,"type":22},100,"6 Months","Primary objective of this study is to introduce a modified luminous efficiency function that addresses the distinct total eye light transmittance of patients who underwent pseudophakic presbyopic correction with extended-depth of focus (EDOF) intraocular lenses (IOLs) implantations.",[61],"Presbyopia",[63,64,65,66,67],"pseudophakic presbyopic correction","EDOF intraocular lens","light intensity","eye light transmittance","light efficiency function","RECRUITING","2026-02-23",{"date":71,"type":37},"2026-02-24",{"date":73,"type":37},"2025-10-15",{"date":75,"type":22},"2026-12-15",{"name":43,"class":44},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":54,"sex":17,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":89,"studyType":23,"phases":4,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":45},"100597569","the-impact-of-artificial-lighting-on-the-visual-capacity-of-patients-with-age-related-macular-degeneration-100597569","NCT07060196","The Impact of Artificial Lighting on the Visual Capacity of Patients With Age-Related Macular Degeneration","The Impact of Artificial Lighting on the Visual Capacity of Patients With Age-Related Macular Degeneration.","ADLs AMD","Inclusion Criteria:\n\n* Healthy controls over the age of 60.\n* Diagnosis of bilateral dry age-related macular degeneration (AMD).\n\nExclusion Criteria:\n\n* Patients with other ocular conditions such as high myopia, glaucoma, clinically significant diabetic retinopathy, and other diseases that may confound the evaluation of ocular outcome measurements.\n* Patients who have undergone intraocular surgeries, except for uncomplicated cataract extraction surgery performed at least 3 months prior to their inclusion in the study.\n* Individuals with systemic diseases, including oxalate kidney stones, Wilson's disease, hemochromatosis, lung cancer, or other illnesses associated with poor five-year survival.\n* Patients with binocular best-corrected distance visual acuity less than or equal to hand motion perception.\n* Patients with neurological, orthopedic, or psychiatric disorders that prevent them from completing the activities or conditions that may affect their performance.","60 Years","100 Years",{"count":88,"type":22},70,"15 Days","Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in the elderly worldwide. The dry, non-exudative form of the disease, although more common, is associated with gradual and significant decline in functional vision. Despite advancements in diagnostic and therapeutic approaches, a targeted intervention that improves the daily functionality of these patients is still lacking. One critical, yet often overlooked, factor that affects daily performance is lighting conditions.\n\nThis study aims to objectively assess the impact of different lighting intensity levels on patients with advanced dry AMD during the execution of everyday activities. A total of 60 individuals will be evaluated (30 healthy controls over 60 years of age and 30 patients with clinically diagnosed advanced AMD, according to NICE and AREDS criteria). Participants will undergo ophthalmological assessment (visual acuity, contrast sensitivity, OCT\u002FOCTA, autofluorescence), and their performance on five functional tasks (mobility, object grasping, sit-to-stand transition, obstacle avoidance, and hanging clothes) will be evaluated under eight lighting levels (20-300 lux) at a constant color temperature (4000K), in a specially designed laboratory equipped with motion and eye-tracking systems.\n\nThe primary endpoint is overall performance, based on task completion time and errors, expressed on a custom performance scale (0-100). Secondary data include changes in pupil size as an indicator of visual adaptation. The study aims to determine the optimal lighting range that maximizes functional vision and improves the quality of life for patients with AMD.",[92],"AMD - Age-Related Macular Degeneration",[94,95,96],"AMD","artificial lighting","ADLs","2025-07-08",{"date":99,"type":37},"2025-07-11",{"date":101,"type":22},"2025-06-30",{"date":103,"type":22},"2027-01-31",{"name":43,"class":44},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":116,"phases":117,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":45},"100564572","phase-3-prevention-of-worsening-renal-function-of-intravenus-albumin-in-heart-failure-patients-100564572","NCT06630923","PREVENTION OF WORSENING RENAL FUNCTION OF INTRAVENUS ALBUMIN IN HEART FAILURE PATIENTS","HUMAN ALBUMIN IN HEART FAILURE - DIORASIS TRIAL","Inclusion Criteria:\n\n1. age over 18 yrs\n2. acute decompensation of CHF\n3. evidence of hepatic dysfunction by laboratory biochemical measurements or imaging (liver ultrasonography)\n4. history of CHF with previous use of an oral loop diuretic\n5. anticipated need for IV diuretic therapy for at least 72 hours\n\nThere is no pre-specified inclusion criterion with respect to ejection fraction\n\nExclusion Criteria:\n\n1. hemodynamic collapse (at least one of the following: systolic blood pressure (BP) \\\u003C 90 mmHg, or BP drop by \\>= 40 mmHg for \\>= 15 min, with end-organ hypoperfusion; need for inotropes (except of digoxin); need for cardiopulmonary resuscitation).\n2. hepatic dysfunction of other than cardiac etiology\n3. severe anemia (Hb\\\u003C8 g\u002FdL)\n4. uncontrolled hypertension or hypertensive emergency\u002Furgency\n5. pulmonary edema or pulmonary congestion necessitating use of IV vasodilators\n6. serum creatinine \\> 3 mg\u002FdL or glomerular filtration rate (GFR) \\\u003C 30 ml\u002Fmin","18 Years","95 Years",{"count":115,"type":22},250,"INTERVENTIONAL",[118],"PHASE3","Patients hospitalized for acute decompensation of CHF are usually complicated by worsening renal function (WRF) which leads to diuretic resistance and inadequate decongestion as well as poor prognosis. WRF has been attributed to a reflex renal vasoconstriction elicited by intravascular volume depletion during brisk diuresis. The investigators hypothesize that CHF patients with hepatic dysfunction are more prone to WRF due to poor albumin production. This sub-group of CHF patients may benefit more (increased diuretic efficacy and protected against worsening renal function) by the use of IV loop diuretics in combination with an intravascular volume expander such as IV Human Albumin.",[121,122,123],"Diuretics Drug Reactions","Heart Failure; With Decompensation","Albumin; Double",[125,126,127],"Human Albumin","Furosemide","Heart Failure","2024-10-04",{"date":130,"type":37},"2024-10-08",{"date":132,"type":37},"2023-01-14",{"date":134,"type":22},"2026-12-11",{"name":43,"class":44},""]